Mergers and Acquisitions were again the story of 2015 with over 160 deals announced (not all are completed) in 2015, as compared with 137 in 2014. This trend will continue in 2016 as pharma companies look to address the continued pain of patent expirations, declining R&D productivity and pricing pressure. We saw only a 2% growth in the revenue for the top 50, adding $20B to 2014’s $834B to ring in at $854B as compared with an 18% revenue increase for the top 50 Biotech companies adding $10B.
The future looks bright with the FDA Novel Drug approvals up in 2015. The CDER approved 45 novel drugs, 16 of which were first in class, and 47% were for rare or “orphan diseases”. Other notable events for the pharmaceutical industry in 2015 include significant high-profile mergers in the PBM landscape and the first biosimilar approval. And of course, it is impossible to close the commentary on 2015 without mentioning Turing Pharmaceutical’s 5,000% increase which only added fuel to the debate on high drug prices.
Here’s a snapshot of where the Top 50 (based on revenue) were at year’s end. Companies are ranked by their 2015 revenue as furnished by their annual reports, earnings press releases and publicly available sources such as Edgar and Morningstar stock information websites. Figures of non-U.S. companies who did not report earnings in U.S dollars were converted to U.S. dollars based XE currency data as of 12/31/15. Companies with fiscal year end dates in 2015 that are prior to 12/31/15 have their revenue listed as 2015 revenue.
Companies are ranked by their 2015 revenue as furnished by their annual reports and publicly available sources such as Edgar and Morningstar stock information websites. Figures of non-U.S. companies were converted to U.S. dollars from various currencies.
CLICK HERE TO RECEIVE YOUR COPY OF THE TOP 50 PHARMA COMPANIES